Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen

Welkom bij THIM Hogeschool voor Fysiotherapie & Bohn Stafleu van Loghum

THIM Hogeschool voor Fysiotherapie heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen. Je kunt je links eenvoudig registreren. Met deze gegevens kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL. Heb je een vraag, neem dan contact op met helpdesk@thim.nl.

» Andere revante producten voor THIM studenten en medewerkers.

Registreer

Om ook buiten de locaties van THIM, thuis bijvoorbeeld, van Mijn BSL gebruik te kunnen maken, moet je jezelf eenmalig registreren. Dit kan alleen vanaf een computer op een van de locaties van THIM.

Eenmaal geregistreerd kun je thuis of waar ook ter wereld onbeperkt toegang krijgen tot Mijn BSL.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Inloggen
Top
Netherlands Heart Journal
Gepubliceerd in:

01-11-2008 | original article

Restenosis begets restenosis: implications for stent selection

Auteurs: J. S. Wijpkema, R. L. Anthonio, G. A. J. Jessurun, W. A. Dijk, R. A. Tio, F. Zijlstra

Gepubliceerd in: Netherlands Heart Journal | Uitgave 11/2008

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Extract

Since the introduction of coronary angioplasty, restenosis has been a key problem after this procedure. In the early 1990s, intracoronary stenting was introduced to reduce complication as well as recurrence rates.1,2 Although this technique greatly improved immediate and long-term results, restenosis still remained a challenge. In 2002, drug-eluting stents (DES) were introduced to further decrease the risk of restenosis.3-5 However, the costs of these stents are high and cost-effectiveness of DES compared with bare metal stents remains an issue of debate.6,7 Furthermore, it has been shown recently that DES have an increased risk of developing late stent thrombosis.8-10 Therefore, an important field of research is to identify which patients will benefit in particular from DES and which patients will have a good outcome with a bare-metal stent. …
vorige artikel Coronary artery anomalies detected by MSCT-coronary angiography in the adult
volgende artikel The distal aorta in the Marfan syndrome
Literatuur
1.
Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
2.
Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-95.
3.
Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban HE, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
4.
Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
5.
Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004;292:2727-34.
6.
Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005;366:921-9.
7.
van Hout BA, Serruys PW, Lemos PA, van den Brand MJ, van Es GA, Lindeboom WK, et al. One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial. Heart 2005;91:507-12.
8.
Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-61.
9.
Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
10.
Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78.
11.
Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR, Jr., Spanos V, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004; 109:1244-9.
12.
Iakovou I, Ge L, Michev I, Sangiorgi GM, Montorfano M, Airoldi F, et al. Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions. J Am Coll Cardiol 2004;44:967-71.
13.
Hoffmann R, Mintz GS, Mehran R, Pichard AD, Kent KM, Satler LF, et al. Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz-Schatz stents. J Am Coll Cardiol 1998,31:43-9.
14.
Gyongyosi M, Yang P, Khorsand A, Glogar D. Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events. Austrian Wiktor Stent Study Group and European Paragon Stent Investigators. J Am Coll Cardiol 2000;35:1580-9.
15.
Hirshfeld JW Jr, Schwartz JS, Jugo R, MacDonald RG, Goldberg S, Savage MP, et al. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-HEART Investigators. J Am Coll Cardiol 1991;18:647-56.
16.
Kastrati A, Schomig A, Elezi S, Dirschinger J, Mehilli J, Schuhlen H, et al. Prognostic value of the modified American College of Cardiology/American Heart Association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. Circulation 1999;100:1285-90.
17.
Kastrati A, Elezi S, Dirschinger J, Hadamitzky M, Neumann FJ, Schomig A. Influence of lesion length on restenosis after coronary stent placement. Am J Cardiol 1999;83:1617-22.
18.
Sinitsyn V, Belkind M, Matchin Y, Lyakishev A, Naumov V, Ternovoy S. Relationships between coronary calcification detected at electron beam computed tomography and percutaneous trans-luminal coronary angioplasty results in coronary artery disease patients. Eur Radiol 2003;13:62-7.
19.
Agema WR, Monraats PS, Zwinderman AH, De Winter RJ, Tio RA, Doevendans PA, et al. Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. Eur Heart J 2004;25:1163-70.
20.
Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997;30:1428-36.
21.
Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004;109:476-80.
22.
Agema WR, Jukema JW, Pimstone SN, Kastelein JJ. Genetic aspects of restenosis after percutaneous coronary interventions: towards more tailored therapy. Eur Heart J 2001;22:2058-74.
23.
Monraats PS, Rana JS, Zwinderman AH, De Maat MP, Kastelein JP, Agema WR, et al. -455G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement. Thromb Haemost 2005;93:564-9.
24.
Monraats PS, Rana JS, Nierman MC, Pires NM, Zwinderman AH, Kastelein JJ, et al. Lipoprotein lipase gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention. J Am Coll Cardiol 2005;46:1093-100.
25.
Hoppmann P, Koch W, Schomig A, Kastrati A. The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percutaneous coronary interventions. Eur Heart J 2004;25:335-41.
26.
Gorchakova O, Koch W, von BN, Mehilli J, Schomig A, Kastrati A. Association of a genetic variant of endothelial nitric oxide synthase with the 1 year clinical outcome after coronary stent placement. Eur Heart J 2003;24:820-7.
27.
Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004;350:232-8.
28.
Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
29.
Wijpkema JS, Jessurun GA, Van Boven AJ, Versteeg DI, Hautvast RW, Tio RA. Clinical impact of abciximab on long-term outcome after complex coronary angioplasty. Catheter Cardiovasc Interv 2003;60:339-43.
30.
Arjomand H, Willerson JT, Holmes DR, Jr., Bamlet WR, Surabhi SK, Roukoz B, et al. Outcome of patients with prior percutaneous revascularization undergoing repeat coronary intervention (from the PRESTO Trial). Am J Cardiol 2005;96:741-6.
31.
de Feyter PJ, Kay P, Disco C, Serruys PW. Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary angiog-raphy. Circulation 1999;100:1777-83.
32.
Singh M, Gersh BJ, McClelland RL, Ho KK, Willerson JT, Penny WF, et al. Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. J Am Coll Cardiol 2005;45:198-203.
33.
Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-47.
Metagegevens
Titel
Restenosis begets restenosis: implications for stent selection
Auteurs
J. S. Wijpkema
R. L. Anthonio
G. A. J. Jessurun
W. A. Dijk
R. A. Tio
F. Zijlstra
Publicatiedatum
01-11-2008
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Netherlands Heart Journal / Uitgave 11/2008
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI
https://doi.org/10.1007/BF03086182

Andere artikelen Uitgave 11/2008

The distal aorta in the Marfan syndrome

  • review article

Coronary artery anomalies detected by MSCT-coronary angiography in the adult

  • original article

Intermittent spastic coronary occlusion at site of non-significant atherosclerotic lesion requiring stent implantation

  • imaging in cardiology

ESC Congress 2008 in Munich: Hot news from Hot lines!

  • editorial

A rare combination of coronary anomalies

  • case report